What is the appropriate antibiotic regimen for a patient with persistent hematuria, dysuria, urinary frequency and urgency, whose urine culture grew β‑hemolytic Group B streptococcus (≈20,000 CFU/mL) susceptible to ampicillin/penicillin after failing nitrofurantoin (Macrobid) and amoxicillin, and who has an upcoming urology appointment?

Treatment Recommendation for Group B Streptococcus UTI

This patient requires oral amoxicillin 500 mg every 8 hours for 7-10 days to treat the Group B Streptococcus urinary tract infection. The organism is confirmed susceptible to ampicillin/penicillin, and this represents a complicated UTI given the persistent symptoms despite two prior antibiotic courses.

Why This Specific Regimen

The culture shows β-hemolytic Group B Streptococcus (GBS) at 20,000 CFU/mL with documented susceptibility to ampicillin and penicillin. While this colony count is below the traditional 100,000 CFU/mL threshold, the persistent symptoms (hematuria, dysuria, frequency, urgency) after two treatment courses indicate true infection rather than colonization.

Amoxicillin is the appropriate choice here because:

• GBS remains universally susceptible to β-lactam antibiotics 1, 2
• The FDA label confirms amoxicillin 500 mg every 8 hours is the standard dose for genitourinary tract infections of moderate severity 3
• This is a complicated UTI (failed prior therapy, persistent symptoms) requiring 7-10 days of treatment 4

Why Previous Antibiotics Failed

Nitrofurantoin (Macrobid) failure: Nitrofurantoin has poor activity against Group B Streptococcus. The 2011 IDSA guidelines explicitly state that β-lactams have superior efficacy for streptococcal UTIs 5. Macrobid is designed primarily for E. coli and other gram-negative organisms.

Amoxicillin failure: The prior amoxicillin course likely failed due to inadequate duration or dosing. The patient needs the full genitourinary tract dose (500 mg every 8 hours, not the lower 250 mg dose) for adequate duration 3.

Treatment Duration and Monitoring

Duration: 7-10 days minimum. The 2024 EAU guidelines recommend 7-14 days for complicated UTIs 4. Given two prior treatment failures, aim for 10 days. The FDA label specifies treatment should continue 48-72 hours beyond symptom resolution 3.

For the hematuria specifically: Recent data shows microhematuria from UTI typically resolves by 12 weeks post-treatment 6. Do not recheck urinalysis before 4 weeks, as earlier testing often shows persistent hematuria that would resolve spontaneously. Optimal timing for confirmatory UA is around 12 weeks.

Critical Pitfalls to Avoid

1. Do not use fluoroquinolones empirically. While the 2024 EAU guidelines allow ciprofloxacin for complicated UTIs 4, this patient has culture-directed therapy showing penicillin susceptibility. Fluoroquinolones should be reserved for resistant organisms 5.

2. Do not discontinue therapy early. GBS requires full treatment duration. Research shows accelerated killing with combination therapy (ampicillin + gentamicin) 7, 8, but for outpatient oral therapy, adequate duration with amoxicillin alone is essential.

3. Do not use trimethoprim-sulfamethoxazole. Despite one case report of successful TMP-SMX treatment for GBS urethritis 9, the IDSA guidelines explicitly state amoxicillin/ampicillin should not be used empirically but ARE appropriate for culture-directed therapy when susceptibility is confirmed 5.

Coordination with Urology

The patient has an upcoming urology appointment. Continue the full antibiotic course regardless of the appointment timing. The urologist will need to evaluate for:

• Anatomic abnormalities causing recurrent infection
• Incomplete bladder emptying
• Urinary tract obstruction
• Other complicating factors 4

The 2024 EAU guidelines emphasize that managing the underlying urological abnormality is mandatory for complicated UTIs 4. The antibiotic treats the infection, but the urologist must address why this patient had treatment failures.

Alternative if Penicillin Allergy

If the patient had true penicillin allergy (not mentioned in this case), options would include:

• Vancomycin (for severe allergy) - GBS remains universally susceptible 1, 10
• Clindamycin - only if susceptibility confirmed (4% resistance rate) 2
• NOT erythromycin - 21% resistance rate makes this unreliable 2